Fate Therapeutics (FATE) Short Interest Ratio & Short Volume $1.13 +0.19 (+20.69%) Closing price 08/13/2025 04:00 PM EasternExtended Trading$1.16 +0.03 (+2.21%) As of 08/13/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Fate Therapeutics Short Interest DataFate Therapeutics (FATE) has a short interest of 9.46 million shares. This marks a -0.84% decrease in short interest from the previous month. The short interest ratio (days to cover) is 5.2, indicating that it would take 5.2 days of the average trading volume of 1.31 million shares to cover all short positions.Current Short Interest9,460,000 sharesPrevious Short Interest9,540,000 sharesChange Vs. Previous Month-0.84%Dollar Volume Sold Short$10.69 millionShort Interest Ratio5.2 Days to CoverLast Record DateJuly 15, 2025Outstanding Shares114,600,000 sharesPercentage of Shares Shorted8.25%Today's Trading Volume5,380,222 sharesAverage Trading Volume1,306,353 sharesToday's Volume Vs. Average412% Short Selling Fate Therapeutics? Sign up to receive the latest short interest report for Fate Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartFATE Short Interest Over TimeFATE Days to Cover Over TimeFATE Percentage of Float Shorted Over Time Fate Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/15/20259,460,000 shares $10.69 million -0.8%N/A5.2 $1.13 6/30/20259,540,000 shares $10.68 million +0.3%8.8%4.7 $1.12 6/15/20259,510,000 shares $12.13 million -13.9%8.8%4.6 $1.28 5/31/202511,050,000 shares $13.65 million -14.1%10.2%5.5 $1.24 5/15/202512,870,000 shares $13.00 million -3.5%11.9%5.9 $1.01 4/30/202513,340,000 shares $17.08 million -14.4%N/A5.6 $1.28 4/15/202515,590,000 shares $17.46 million -4.8%14.4%6.8 $1.12 3/31/202516,370,000 shares $12.93 million +12.4%15.1%7 $0.79 3/15/202514,570,000 shares $13.72 million +9.3%13.5%5.8 $0.94 2/28/202513,330,000 shares $14.93 million +2.1%12.3%4.8 $1.12 Get the Latest News and Ratings for FATE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/15/202513,060,000 shares $18.55 million +1.5%12.1%4.4 $1.42 1/31/202512,870,000 shares $16.73 million +1.3%N/A4.2 $1.30 1/15/202512,700,000 shares $16.76 million +13.4%N/A4.1 $1.32 12/31/202411,200,000 shares $18.48 million -8.1%N/A3.8 $1.65 12/15/202412,190,000 shares $22.31 million +7.4%N/A4.5 $1.83 11/30/202411,350,000 shares $35.98 million +9.2%N/A5 $3.17 11/15/202410,390,000 shares $20.99 million -34.7%N/A5.4 $2.02 10/31/202415,900,000 shares $37.68 million -1.0%N/A12.6 $2.37 10/15/202416,060,000 shares $48.98 million +13.3%N/A12.2 $3.05 9/30/202414,180,000 shares $49.63 million -5.7%N/A8.8 $3.50 9/15/202415,040,000 shares $60.46 million -0.9%N/A9.2 $4.02 8/31/202415,170,000 shares $55.67 million +8.9%N/A8.1 $3.67 8/15/202413,930,000 shares $47.22 million +0.9%N/A6.8 $3.39 7/31/202413,800,000 shares $73.55 million -32.0%N/A6.1 $5.33 7/15/202420,290,000 shares $78.93 million +2.1%N/A8.3 $3.89 6/30/202419,870,000 shares $65.17 million -6.1%N/A8.5 $3.28 6/15/202421,150,000 shares $76.35 million -5.3%N/A8.7 $3.61 5/31/202422,340,000 shares $82.21 million +7.4%N/A8.8 $3.68 5/15/202420,810,000 shares $88.23 million -6.0%N/A8 $4.24 4/30/202422,140,000 shares $87.45 million +17.0%N/A8.5 $3.95 4/15/202418,920,000 shares $106.71 million +14.7%N/A6.8 $5.64 3/31/202416,490,000 shares $121.04 million +25.3%19.0%5.8 $7.34 3/15/202413,160,000 shares $98.57 million -2.5%15.2%4.6 $7.49 2/29/202413,490,000 shares $95.64 million +1.4%15.6%5.1 $7.09 2/15/202413,310,000 shares $94.23 million +15.9%15.5%5.3 $7.08 1/31/202411,480,000 shares $70.72 million +6.6%12.4%4.7 $6.16 1/15/202410,770,000 shares $49.00 million +2.1%11.6%5.3 $4.55 12/31/202310,550,000 shares $39.46 million -2.1%11.4%5.8 $3.74 12/15/202310,780,000 shares $32.56 million -7.9%11.6%6.3 $3.02 11/30/202311,710,000 shares $29.16 million +0.9%12.6%5.6 $2.49Tesla is in trouble (Ad)This company is the lifeblood of AI data centers, yet almost no one has caught up with the story. Their hardware is so essential that the data center industry uses enough of it to stretch around the world 8 times – in a single building! So, if you own Nvidia stock now, you might be well-served to sell those shares and check out this under-the-radar play instead. Or if you missed the boat on Nvidia, this is a rare second chance to target tremendous profit potential as AI data centers spring up in every corner of the world.Get my full take on this exciting play right here… 11/15/202311,610,000 shares $28.79 million -1.6%12.5%5.3 $2.48 10/31/202311,800,000 shares $21.36 million -14.5%12.7%5.2 $1.81 10/15/202313,800,000 shares $23.46 million -7.4%14.9%6.1 $1.70 9/30/202314,900,000 shares $31.59 million -38.7%16.1%6.6 $2.12 9/15/202324,290,000 shares $53.44 million -12.1%26.2%10.7 $2.20 8/31/202327,640,000 shares $69.38 million -2.3%29.8%12.7 $2.51 8/15/202328,290,000 shares $82.89 million +2.4%30.5%13.2 $2.93 7/31/202327,630,000 shares $114.11 million +7.6%29.9%12.9 $4.13 7/15/202325,670,000 shares $121.42 million -1.0%27.8%11.5 $4.73 6/30/202325,930,000 shares $123.43 million -11.9%28.1%10.6 $4.76 6/15/202329,440,000 shares $171.05 million +1.1%31.9%11.7 $5.81 5/31/202329,120,000 shares $147.06 million 0.0%31.5%11.2 $5.05 5/15/202329,130,000 shares $155.26 million +3.7%31.6%10.8 $5.33 4/30/202328,080,000 shares $170.45 million +4.3%30.7%10.3 $6.07 4/15/202326,920,000 shares $161.79 million -1.5%29.5%9.7 $6.01 3/31/202327,340,000 shares $155.84 million +26.7%30.0%9.1 $5.70 3/15/202321,580,000 shares $119.98 million +15.7%23.6%5.4 $5.56 2/28/202318,660,000 shares $114.20 million +10.7%20.4%5.1 $6.12 2/15/202316,850,000 shares $106.83 million +3.5%18.7%4.9 $6.34 1/31/202316,280,000 shares $97.03 million +5.4%17.8%4.9 $5.96 1/15/202315,450,000 shares $83.43 million -30.8%16.9%4.9 $5.40 12/30/202222,330,000 shares $225.31 million +10.3%24.5%7.8 $10.09 12/15/202220,240,000 shares $287.61 million -4.6%22.2%13.5 $14.21 11/30/202221,220,000 shares $441.80 million -4.1%23.2%16.6 $20.82 11/15/202222,120,000 shares $492.83 million -0.5%24.2%16.8 $22.28 10/31/202222,230,000 shares $465.05 million +2.1%24.4%16.3 $20.92 10/15/202221,780,000 shares $443.44 million +0.7%24.0%16.5 $20.36 9/30/202221,620,000 shares $484.50 million +3.9%23.8%16.5 $22.41 9/15/202220,800,000 shares $562.64 million +2.8%22.9%15 $27.05 8/31/202220,240,000 shares $529.07 million +1.6%22.3%13.6 $26.14 8/15/202219,920,000 shares $718.32 million -5.6%21.9%12.9 $36.06 7/31/202221,100,000 shares $644.18 million -0.6%23.3%13 $30.53 7/15/202221,220,000 shares $672.67 million -3.6%23.4%12.9 $31.70 6/30/202222,010,000 shares $545.41 million +6.8%24.4%13.6 $24.78 6/15/202220,600,000 shares $399.23 million +0.6%36.4%13.1 $19.38 5/31/202220,470,000 shares $472.86 million +14.4%22.6%14.3 $23.10 5/15/202217,900,000 shares $433.54 million +8.2%19.8%12.8 $24.22 4/30/202216,550,000 shares $472.67 million +3.4%18.3%12.9 $28.56 4/15/202216,000,000 shares $604.32 million +3.8%17.8%12.2 $37.77 3/31/202215,420,000 shares $597.83 million -1.7%17.1%11.3 $38.77 3/15/202215,690,000 shares $491.25 million +2.0%17.4%11.5 $31.31 2/28/202215,390,000 shares $531.72 million +11.9%17.1%10.8 $34.55 2/15/202213,760,000 shares $521.23 million +9.6%15.4%10 $37.88 1/31/202212,550,000 shares $520.95 million +7.5%14.0%9.8 $41.51 1/15/202211,670,000 shares $505.08 million +1.6%13.0%9.5 $43.28 12/31/202111,490,000 shares $672.28 million +6.3%12.8%10.2 $58.51 12/15/202110,810,000 shares $590.98 million -0.4%12.0%9.8 $54.67 11/30/202110,850,000 shares $596.86 million +7.0%12.1%11.7 $55.01 11/15/202110,140,000 shares $544.82 million -1.8%11.3%10.9 $53.73 10/29/202110,330,000 shares $555.75 million -3.9%11.6%9.7 $53.80Tesla is in trouble (Ad)This company is the lifeblood of AI data centers, yet almost no one has caught up with the story. Their hardware is so essential that the data center industry uses enough of it to stretch around the world 8 times – in a single building! So, if you own Nvidia stock now, you might be well-served to sell those shares and check out this under-the-radar play instead. Or if you missed the boat on Nvidia, this is a rare second chance to target tremendous profit potential as AI data centers spring up in every corner of the world.Get my full take on this exciting play right here… 10/15/202110,750,000 shares $658.33 million -5.7%12.1%10.2 $61.24 9/30/202111,400,000 shares $675.68 million -3.4%12.8%11.4 $59.27 9/15/202111,800,000 shares $784.70 million -1.2%13.2%12 $66.50 8/31/202111,940,000 shares $874.61 million -3.1%13.4%11.6 $73.25 8/13/202112,320,000 shares $1.07 billion +0.8%13.8%12.2 $86.71 7/30/202112,220,000 shares $1.01 billion +5.0%13.7%13 $82.80 7/15/202111,640,000 shares $892.79 million -1.7%13.2%12 $76.70 6/30/202111,840,000 shares $1.03 billion +0.4%13.4%12.1 $86.79 6/15/202111,790,000 shares $1.02 billion -3.1%13.4%11.4 $86.79 5/28/202112,170,000 shares $932.22 million -6.5%13.8%12 $76.60 5/14/202113,020,000 shares $931.06 million +6.5%N/A12.9 $71.51 4/30/202112,230,000 shares $1.05 billion +1.3%N/A12.2 $85.87 4/15/202112,070,000 shares $1.02 billion +0.1%N/A12.3 $84.73 3/31/202112,060,000 shares $893.53 million +4.3%N/A11.6 $74.09 3/15/202111,560,000 shares $1.09 billion +12.2%N/A11.2 $93.99 2/26/202110,300,000 shares $888.58 million +7.0%N/A8.2 $86.27 2/12/20219,630,000 shares $987.08 million -4.5%N/A8 $102.50 1/29/202110,080,000 shares $916.37 million -0.8%N/A8.7 $90.91 1/15/202110,160,000 shares $1.19 billion -8.0%N/A8.9 $117.40 12/31/202011,040,000 shares $1.03 billion -15.6%N/A9.7 $93.62 12/15/202013,080,000 shares $1.26 billion -9.2%N/A12.2 $96.38 11/30/202014,400,000 shares $834.05 million +0.9%N/A13.2 $57.92 11/15/202014,270,000 shares $720.78 million -0.6%N/A16 $50.51 10/30/202014,350,000 shares $654.79 million -3.6%N/A16.7 $45.63 10/15/202014,880,000 shares $698.76 million +7.1%N/A17.4 $46.96 9/30/202013,900,000 shares $555.58 million +7.6%N/A17.2 $39.97 9/15/202012,920,000 shares $485.28 million +1.9%N/A16.2 $37.56 8/31/202012,680,000 shares $461.55 million +2.6%N/A16.2 $36.40 8/14/202012,360,000 shares $425.31 million +1.4%N/A13.6 $34.41 FATE Short Interest - Frequently Asked Questions What is Fate Therapeutics' current short interest? Short interest is the volume of Fate Therapeutics shares that have been sold short but have not yet been closed out or covered. As of July 15th, investors have sold 9,460,000 shares of FATE short. Learn More on Fate Therapeutics' current short interest. What is a good short interest ratio for Fate Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. FATE shares currently have a short interest ratio of 5.0. Learn More on Fate Therapeutics's short interest ratio. Which institutional investors are shorting Fate Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Fate Therapeutics: Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Fate Therapeutics' short interest increasing or decreasing? Fate Therapeutics saw a decrease in short interest in July. As of July 15th, there was short interest totaling 9,460,000 shares, a decrease of 0.8% from the previous total of 9,540,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Fate Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Fate Therapeutics: Kodiak Sciences Inc. (5.12%), Kamada Ltd. (0.30%), Erasca, Inc. (12.31%), Cullinan Therapeutics, Inc. (16.37%), COMPASS Pathways PLC Sponsored ADR (9.15%), Prothena Corporation plc (11.25%), Tectonic Therapeutic, Inc. (18.11%), PureTech Health PLC Sponsored ADR (0.02%), CryoPort, Inc. (5.63%), Gossamer Bio, Inc. (7.97%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Coinbase Global, Inc. ($5.11 billion), Charter Communications, Inc. ($4.76 billion), Reddit Inc. ($2.84 billion), SoFi Technologies, Inc. ($2.79 billion), Seagate Technology Holdings PLC ($2.79 billion), Live Nation Entertainment, Inc. ($2.67 billion), Rocket Lab Corporation ($2.49 billion), AST SpaceMobile, Inc. ($2.12 billion), Moderna, Inc. ($2.09 billion), and Omnicom Group Inc. ($2.04 billion). View all of the most shorted stocks. What does it mean to sell short Fate Therapeutics stock? Short selling FATE is an investing strategy that aims to generate trading profit from Fate Therapeutics as its price is falling. FATE shares are trading up $0.19 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Fate Therapeutics? A short squeeze for Fate Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of FATE, which in turn drives the price of the stock up even further. How often is Fate Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including FATE, twice per month. The most recent reporting period available is July, 15 2025. More Short Interest Resources from MarketBeat Related Companies KOD Short Squeeze KMDA Short Squeeze ERAS Short Squeeze CGEM Short Squeeze CMPS Short Squeeze PRTA Short Squeeze TECX Short Squeeze PRTC Short Squeeze CYRX Short Squeeze GOSS Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:FATE) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access